Sharon Golden
Adult Health · Grand Junction, CONPI 1366718017
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $27.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$667
- AbbVie$378
- Novartis$360
- Lilly USA, LLC$288
- Biohaven Pharmaceuticals, Inc.$241
- Genentech USA, Inc.$227
- plus $1K from 29 others
Across 2 payments — averaging $4200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- TG Therapeutics, Inc.$8K
What the payments were for
- Speaking & faculty fees$251%
- Food & beverage$3,56399%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 7 | $667 |
| AbbVie(2 entities) | 25 | $378 |
| Novartis | 13 | $360 |
| Lilly USA, LLC | 7 | $288 |
| Biohaven Pharmaceuticals, Inc. | 9 | $241 |
| Genentech USA, Inc. | 5 | $227 |
| Biogen | 6 | $201 |
| Acorda Therapeutics, Inc | 5 | $159 |
| UCB, Inc. | 5 | $103 |
| Livanova USA, Inc. | 1 | $92 |
| Amneal Pharmaceuticals LLC | 4 | $87 |
| SK Life Science, Inc. | 3 | $75 |
| EMD Serono, Inc. | 4 | $75 |
| Merz Pharmaceuticals, LLC | 3 | $65 |
| Amgen(2 entities) | 3 | $63 |
| Neurelis, Inc. | 4 | $55 |
| Lundbeck LLC | 2 | $40 |
| Eisai Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Sanofi | 1 | $33 |
| Bristol Myers Squibb | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Argenx US, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Tanabe Pharma America, Inc. | 1 | $22 |
| Pfizer | 1 | $21 |
| Medtronic | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIUMVI$470
- OCREVUS$148
- NURTEC ODT$120
- KESIMPTA$120
- KISUNLA$113
How this compares
$3,604 in reported general payments places this provider in the 90th percentile of 430 adult health providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 203 | $284,405 |
| Kesimpta PenOfatumumab | 23 | $195,118 |
| EliquisApixaban | 171 | $168,334 |
| Emgality PenGalcanezumab-Gnlm | 178 | $147,499 |
| AmpyraDalfampridine | 20 | $128,746 |
| UbrelvyUbrogepant | 84 | $102,287 |
| QuliptaAtogepant | 65 | $79,473 |
| Austedo XrDeutetrabenazine | 17 | $79,098 |
| Repatha SureclickEvolocumab | 101 | $69,138 |
| BriviactBrivaracetam | 24 | $48,159 |
| XcopriCenobamate | 29 | $32,570 |
| Aimovig AutoinjectorErenumab-Aooe | 21 | $23,327 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 18 | $16,633 |
| ReyvowLasmiditan Succinate | 18 | $16,348 |
| Ajovy SyringeFremanezumab-Vfrm | 21 | $15,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Eliquis | $21 | $452,738374 claims |
| AbbVieUbrelvy, Qulipta | $378 | $181,760149 claims |
| Acorda Therapeutics, IncAmpyra | $159 | $128,74620 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $36 | $79,09817 claims |
| UCB, Inc.Briviact | $103 | $48,15924 claims |
| SK Life Science, Inc.Xcopri | $75 | $32,57029 claims |
| Lilly USA, LLCReyvow, Olanzapine | $288 | $16,97133 claims |
| Johnson & JohnsonXarelto | $12 | $13,71318 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $20 | $10,13311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 430 adult health providers in Colorado.
Other adult health in Grand Junction
- Stefanie EymarAurora$36K
- Jamie ThompsonColorado Springs$31K
- Toni StandleyDenver$23K
- Alexandra GravesAurora$18K
- Keri HalsemaAurora$17K
- Grace WorlandAurora$11K
- Carolyn SchniedersLittleton$11K
- Abbey JonesEnglewood$11K
- Zahra HarrisonColorado Springs$11K
- Nicole GoitiaEnglewood$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.